Covid-19

#BioNTech #Covid-19 #Immunology / Virology & Vaccines #mRNA

BioNTech to deliver prestigious lecture on mRNA  

Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19.   The lecture will be delivered in two halves by Uğur Şahin and Özlem Türeci, co-founders of… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Infectious diseases #WHO

WHO updates Covid-19 strategy to reach unvaccinated  

The World Health Organisation (WHO) has released an update to its ongoing global Covid-19 strategy in order to reach individuals yet to be vaccinated.   The update to WHO’s Global Covid-19 Vaccination Strategy1, was made in response to the spread of Omicron subvariants, advances in vaccine evidence, and… Read More

#News

#Covid-19 #DNA #Drug discovery #Genomics #Infectious diseases

This week in drug discovery (18 -22 July)

News round-up by DDW’s Reece Armstrong for 18 – 22 July Covid-19 vaccines remain effective six months after second dose  Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.   New combination therapy… Read More

#News

#AstraZeneca #BioNTech #Covid-19 #Pfizer

Covid-19 vaccines remain effective six months after second dose

Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.  A study1 led by researchers at the University of Bristol found that two doses of Pfizer-BioNTech and AstraZeneca Covid-19 vaccines provided protection against Covid-19 infections six months… Read More

#Covid-19 #News

Audience
#BioLago #Covid-19 #Immunology / Virology & Vaccines

BioLago’s ‘Science meets business’ event makes successful return 

After a two-year break, the cross-border health network BioLago’s in-person forum returned: ‘Science meets business’ took place 8 July 2022 at the University of Konstanz, Germany.   Around 70 people attended the afternoon forum and networking event, with visitors ranging from technology and service providers, academics, researchers, and… Read More

#News

Covid-19 vaccines
#Covid-19 #Novavax

Novavax looks to expand Covid-19 vaccine authorisation  

Pharmaceutical company Novavax is attempting to expand the use of its Covid-19 vaccine Nuvaxovid into adolescents aged 12-17 year and as a booster dose for adults.   The company has submitted a request to Swissmedic to expand the conditional marketing authorisation (CMA) of Nuvaxovid. The request is based… Read More

#Covid-19 #News

#Antimicrobial resistance (AMR) #Covid-19 #Immunology / Virology & Vaccines

This week in drug discovery (July 4-8)

A Covid-19 lawsuit, a heart attack treatment developed using spider venom and a collaboration to fight antimicrobial resistance (AMR) are some of the theme’s of this week’s news round-up.  News round-up by DDW’s Reece Armstrong for 4 – 8 July. CureVac lawsuit against BioNTech over Covid-19 vaccine technology Biopharmaceutical… Read More

#News

#BioNTech #Covid-19 #CureVac #mRNA #Pfizer

CureVac lawsuit against BioNTech over Covid-19 vaccine technology  

Biopharmaceutical company CureVac has filed a lawsuit against BioNTech SE and two of its subsidiaries in relation to an alleged infringement of the company’s portfolio used in the manufacture and sale of the Comirnaty Covid-19 vaccine.  CureVac has filed the lawsuit in the German Regional Court in… Read More

#News

#Assay #Covid-19 #Monkeypox

This week in drug discovery (27 – 30 June)

News round-up by DDW’s Reece Armstrong for 27 – 30 June. Assays for monkeypox, Covid-19 boosters and approvals for oncology drugs are some of the themes of this week’s news round-up. GSK & Sanofi first to report positive data for Omicron booster   GSK and Sanofi have reported positive efficacy… Read More

#News

Monoclonal antibodies
#Biomarkers #Covid-19 #Immunotherapy

The emergence of reliable immunochemistry

Suchita Gupta examines the immunochemistry reagents market post Covid-19. Immunohistochemistry (IHC) is referred to as the study of a branch of chemistry including the study of various components and functions of the immune system with the application of antigen & antibodies as chemical reagents. It is a technique that combines… Read More

#Exclusive Content

#Covid booster #Covid-19 #Sanofi-GSK #Vaccines

GSK & Sanofi first to report positive data for Omicron booster  

GSK and Sanofi have reported positive efficacy data from a co-developed vaccine targeting the Omicron variant of Covid-19.   The report makes GSK and Sanofi the first companies to have a vaccine candidate for the Omicron variant which has demonstrated efficacy.  Specifically, the companies’ B.1.351… Read More

#Covid-19 #News

#Covid-19 #GSK #Infectious diseases #Vaccines

GSK invests into infectious disease research for low-income countries  

GSK is to invest £1 billion over the course of 10 years into research on infectious diseases that largely affect low-income countries.   In particular, the pharmaceutical company will aim to develop new vaccines and medicines that prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical… Read More

#News

#Appointment #Cell and gene therapy #Covid-19 #Diversity #HIV #Vaccines

This week in drug discovery (20-24 June)

News round-up by DDW’s Reece Armstrong for 20-24 June. Covid-19 vaccine development and research, gene therapies for dementia and a ‘game-changing’ treatment for HIV are some of the themes of this week’s news round-up. Moderna to set up mRNA vaccine centre in UK  Pharmaceutical company Moderna is to set-up… Read More

#News

#Covid-19 #Manufacturing #mRNA

Moderna to set up mRNA vaccine centre in UK 

Pharmaceutical company Moderna is to set-up a manufacturing and research development centre in the UK following an agreement with the government.   The new mRNA Innovation and Technology Centre will develop mRNA vaccines for respiratory diseases including Covid-19 vaccines that can protect against multiple variants. The aim for… Read More

#News

#Covid-19 #mRNA

Collaboration to develop African-owned Covid-19 vaccine 

A collaboration between two biotech companies hopes to pave the way for the development of the first-ever African-owned Covid-19 vaccine.  Afrigen Biologics and the Univercells Group have announced a collaboration to focus on the development of a new mRNA vaccine. The collaboration is being supported by mRNA specialist, eTheRNA, and… Read More

#Covid-19 #News